177Lu-PSMA I&T Composition for Reduced Healthy-Organ Radiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing 177Lu-PSMA I&T formulations for prostate cancer treatment result in undesirable absorbed doses of radiation to healthy organs, necessitating a need for improved compositions and methods that minimize radiation exposure to non-targeted tissues and organs.
Innovation Solution
The development of 177Lu-PSMA I&T compositions with specific molar ratios of PSMA I&T to 177Lu, ranging from 3.0:1.0 to 8.0:1.0, ensuring radiochemical purity ≥95% and stability for 72 hours or more, thereby reducing absorbed radiation doses to organs such as kidneys, lacrimal glands, salivary glands, and liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors (177Lu-PSMA I&T) are used to target PSMA for prostate cancer therapy, then treatment efficacy is improved, but absorbed radiation dose to healthy organs increases
Solution Approach 1:
The patent applies parameter changes by optimizing the molar ratio of PSMA I&T to 177Lu (specifically 3.0:1.0 to 8.0:1.0) and controlling radiochemical purity (≥95%) to achieve effective cancer treatment while minimizing radiation exposure to healthy organs. This precise parameter control allows the formulation to deliver therapeutic radiation to tumor tissue while reducing off-target effects.
2Productivity
If higher radioactivity concentration is used to reduce treatment cycles, then productivity is improved, but radiation exposure to healthy organs increases
Solution Approach 1:
The patent optimizes the radioactivity concentration parameter to a specific range (7.4 GBq ± 15%) in the formulation, which enables effective treatment while controlling the cumulative radiation dose to healthy organs. This parameter optimization allows for extended treatment cycles by balancing therapeutic efficacy with safety margins for organ radiation exposure.
3Stability of the object's composition
If molar ratio of PSMA I&T to 177Lu is increased to maintain radiochemical purity ≥95%, then formulation stability is improved, but amount of radiopharmaceutical available for treatment decreases
Solution Approach 1:
The patent identifies and applies the optimal molar ratio range of PSMA I&T to 177Lu (3.0:1.0 to 8.0:1.0) that simultaneously achieves radiochemical purity ≥95% and maximizes the available radiopharmaceutical quantity for treatment. This parameter optimization resolves the trade-off between formulation stability and therapeutic dosage availability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved compositions achieve lower cumulative absorbed radiation doses to healthy organs, allowing for longer treatment cycles and enhanced safety in prostate cancer therapy.
Implementation Method 1
177Lu-PSMA I&T are small molecule inhibitors of PSMA that are extremely desirable for targeted radionuclide therapy
Implementation Method 2
177Lu has a physical half-life of 6.7 days and emits beta particles (Emax = 0.498 MeV, Emean = 0.133 MeV) with a maximum tissue penetration of 1.7 mm and mean penetration of 0.23 mm
Implementation Method 3
compositions comprising 177Lu-PSMA I&T and methods of administering the same to a human patient in need thereof
Data Source
AI summary
The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.